Introduction {#Sec1}
============

*Family with sequence similarity 13 member A* (*FAM13A*) gene encodes for two proteins, isoform 1 and isoform 2. Isoform 1 contains a RhoGTPase activating protein (RhoGAP) domain known to play a role in cell cycle and proliferation \[[@CR1]\]. Isoform 2 does not include this domain, suggesting that it has a function distinct from isoform 1. Initially, FAM13A was genetically associated with the lung function phenotype \[[@CR2]\], with *FAM13A* genetic variants shown to be associated with lung cancer \[[@CR3], [@CR4]\] and several chronic lung diseases including chronic obstructive pulmonary disease (COPD) \[[@CR5]\], cystic fibrosis (CF) \[[@CR6]\], and idiopathic pulmonary fibrosis (IPF) \[[@CR7]\]. However, despite this overlap of *FAM13A* contribution to chronic lung diseases, the several FAM13A variants have various impacts. Indeed, whether they are associated with an increase or decrease of the expression of the protein, their physiological consequences might be opposite \[[@CR8]\]. Understanding the cellular role of FAM13A in the specific context of each of these diseases is thus essential.

The role of FAM13A in chronic lung diseases starts to be elucidated in various studies. A two-hybrid strategy aiming to identify partners of murine B56 family of phosphatase 2A (PP2A) regulatory subunits, identified FAM13A as a partner \[[@CR9]\]. In COPD, by using affinity purification followed by mass spectrometry in HEK293 cells, the FAM13A isoform 2 has been shown to interact with PP2A and to be involved in the WNT/β-catenin pathway \[[@CR10]\]. In CF, FAM13A is downregulated by Interleukin (IL)-1β and Transforming Growth Factor (TGF)-β, and is involved in the regulation of actin cytoskeleton dynamics and epithelial-mesenchymal transition \[[@CR6]\]. In non-small lung cell cancer, FAM13A was shown to be involved in tumor proliferation downstream of HIF (Hypoxia Inducible Factor)-1α and TGF-β \[[@CR11]\]. Besides, the involvement of FAM13A in IPF is still unknown. Outside the context of lung diseases, at the cellular level, FAM13A is able to control the cell shape \[[@CR12]\].

The aim of this study was to identify the protein partners of the isoform 1 of FAM13A protein in order to decipher the pathways that may be affected in the different chronic lung diseases.

Main text {#Sec2}
=========

Methods {#Sec3}
-------

### Yeast two-hybrid analysis {#Sec4}

Yeast two-hybrid screening was performed by Hybrigenics Services, S.A.S., Paris, France (<http://www.hybrigenics-services.com>). The coding sequence for Human FAM13A full length (NCBI reference NM_014883.2) was from Origene (RC216561, Rockville, MD, USA) and cloned into pB27 as a C-terminal fusion to LexA (LexA-FAM13A). The construct was verified by sequencing the full insert and used as a bait to screen a random-primed Human Lung Cancer cDNA library constructed into pP6, pB27 and pP6 derivatives from the original pBTM116 \[[@CR13]\] and pGADGH \[[@CR14]\] plasmids, respectively. Also, the expected size of the FAM13A protein and RhoGAP activity was previously verified \[[@CR6]\]. The Human Lung Cancer cDNA library is an equimolar mix of three different lung cancer cell lines: A549 (Human lung adenocarcinoma epithelial cell line), H1703 (Human squamous lung cancer cell line, adenocarcinoma; non-small cell lung cancer), H460 (lung carcinoma; large cell lung cancer, epithelial).

### Technical validation {#Sec5}

Screening of 64 million clones (sixfold the complexity of the library) was done using a mating method with YHGX13 (Y187 ade2-101:loxP-kanMX-loxP, matα) and L40∆Gal4 (mata) yeast strains as previously detailed \[[@CR15]\]. 178 His+ colonies were selected on a medium without tryptophan, leucine and histidine, without 3-aminotriazole. The prey fragments of the positive clones were amplified by PCR and sequenced at their 5′ and 3′ junctions. Sequences were then used to identify the corresponding interacting proteins in the GenBank database \[National Center for Biotechnology Information (NCBI)\] using a fully automated procedure. A confidence score (PBS, for predicted biological score) was attributed to each interaction as previously described \[[@CR16]\].

The PBS relies on two different levels of analysis. Firstly, a local score reflects the redundancy and independency of prey fragments, as well as the distribution of reading frames and stop codons in overlapping fragments. Secondly, a global score considers the interactions found in all the screens performed at Hybrigenics (proprietary database) using the same library. This global score represents the probability of an interaction to be nonspecific. The scores were divided into four categories, from A (highest confidence) to D (lowest confidence). A fifth category (E) particularly flags interactions involving highly connected prey domains previously discovered several times in screens accomplished on libraries derived from the same organism. Lastly, F corresponds to numerous of these highly connected domains confirmed as false-positives and are tagged F. The PBS scores have been shown to positively correlate with the biological significance of the interactions \[[@CR17], [@CR18]\].

### Pathway analysis {#Sec6}

Analysis of pathway ontology was realized with freely available PANTHER14.1 Released 2019-03-12 (Protein ANalysis THrough Evolutionary Relationships, <http://pantherdb.org>) \[[@CR19]\]. Statistical enrichment pathway analysis was realized using as options: *Homo sapiens* reference list, PANTHER pathways dataset and Fisher's Exact test followed by the calculation of false discovery rate (FDR).

Results and discussion {#Sec7}
----------------------

We identified 17 proteins interacting with the FAM13A isoform 1, including some already shown to be involved in chronic lung diseases (Table [1](#Tab1){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}).Table 1List of FAM13A interacting proteins detected by two-hybrid-screeningProteinGenePBSAssociation with lung diseaseRef.Cilia- and flagella-associated protein 97*CFAP97*ANoHeat shock cognate 71 kDa protein*HSPA8*AInvolved in CFTR biogenesis and trafficking\[[@CR20]\]Regulated by corticoid in cell lysate of sputum of COPD patients\[[@CR21]\]Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform\**PPP2R5E*\*AGenetically associated with lung cancer\[[@CR22]\]PP2A activity was strongly enhanced in NSCLC\[[@CR23]\]TBC1 domain family member 5*TBC1D5*AInduced by smoking and ozone (murine COPD model)\[[@CR24]\]Filamin-B*FLNB*CNo14-3-3 protein beta/alpha*YWHAB*CInteract with and regulate surfactant protein A2\[[@CR25]\]Involved in lung cancer\[[@CR26]\]Enhancer of mRNA-decapping protein 4*EDC4*CNoTyrosine-protein phosphatase non-receptor type 12*PTPN12*DHigh expression of PTPN12 is associated with favorable survival duration in patients with NSCLC\[[@CR27]\]Histone-lysine N-methyltransferase*SETMAR*DNotRNA cytosine \[[@CR34]\]-C(5)-methyltransferase*NSUN2*DNoRetinal dehydrogenase 1*ALDH1A1*DALDH1 is a lung tumor stem cell-associated marker\[[@CR28]\]ALDH1 expression favorable prognosis in lung adenocarcinoma\[[@CR29]\]Polyubiquitin-B*UBB*DReduced protein expression in COPD lung tissues\[[@CR30]\]Eukaryotic initiation factor 4A-I*EIF4A1*DNoSerine/threonine-protein phosphatase 2A 56 kDa regulatory subunit alpha isoform\*\**PPP2R5A*\*\*ENo14-3-3 protein epsilon*YWHAE*EUpregulated in lung squamous cell carcinoma\[[@CR31]\]14-3-3 protein zeta/delta*YWHAZ*EIdentified as a metastasis enhancer gene in lung cancer\[[@CR32]\]Upregulated in lung cancer\[[@CR33]\]Differentially expressed in malignant bronchial epithelial cell line compared to control cell line\[[@CR34]\]More frequent increased expression in patients with resectable lung adenocarcinoma with an improved prognosis \[[@CR35]\]26S proteasome non-ATPase regulatory subunit 11*PSMD11*FDifferentially expressed in malignant bronchial epithelial cell line compared to control cell line\[[@CR34]\]*PBS* Predicted Biological Score \[[@CR9]\]; *NSCLC* non-small cell lung cancer\*Interaction previously shown using an adult mouse brain library and PPP2R5E (full-length *Xenopus* B56ε) or \*\*mouse FAM13A as bait in two-hybrid screening

Interaction domains are depicted in Fig. [1](#Fig1){ref-type="fig"}. Four proteins were detected with a high predicted Biological Score (PBS): CFAP97, HSPA8, PPP2R5E and TBC1D5. HSPA8 is well known to be involved in Cystic Fibrosis Transmembrane conductance Regulator (CFTR) biogenesis and trafficking \[[@CR20]\]. *CFTR* is the causative gene of CF. This FAM13A-HSPA8 interaction may be important in the role of FAM13A as a modifier of the CF lung phenotype as previously described \[[@CR6]\]. Interestingly, we detected two isoforms of the protein phosphatase 2A (PP2A) B subunit, PPP2R5E and PPP2R5A, previously shown to interact with FAM13A \[[@CR9], [@CR10]\], thus verifying the success of our two-hybrid screening. The PP2A protein has been associated with several lung diseases. In CF, PP2A is known to regulate CFTR activity \[[@CR36]\]. In COPD, FAM13A was shown to recruit PP2A and influence disease susceptibility by promoting β-catenin degradation \[[@CR10]\]. Recent works highlight PP2A as a promising therapeutic target for chronic lung diseases. Indeed, enhancement of PP2A activity was recently shown to reduce cigarette smoke-induced cathepsin S and loss of lung function \[[@CR37]\] and to improve the treatment of tyrosine kinase inhibitor-resistant lung adenocarcinoma \[[@CR38]\]. How FAM13A-PP2A interaction could be involved in these processes remains to be elucidated.Fig. 1Diagram of the proteins identified in the two-hybrid screening and their interaction domains

Pathway enrichment statistical analysis found three major pathways: Fetal Growth Factor (FGF) signaling pathway (FDR = 6.59 × 10^−6^), EGF receptor (EGFR) signaling pathway (FDR = 5.61 × 10^−6^) and Parkinson disease (FDR = 7.01 × 10^−5^) (Fig. [2](#Fig2){ref-type="fig"}). In FGF and EGFR signaling pathways, PP2A B subunit isoforms (PPP2R5A, PPP2R5E) and 14-3-3 proteins (YWHAB, YWHAZ, YWHAE) were shared. 14-3-3 proteins are especially involved in lung cancer \[[@CR39]\]. Interestingly, YWHAB was also shown to interact with surfactant protein A2 (SP-A2) \[[@CR25]\] and genetic variants of YWHAB can predispose individuals to IPF and lung cancer \[[@CR40]\]. Since FAM13A was also genetically associated with IPF and lung cancer, further studies may help to understand the consequences of these interactions in the development of these diseases.Fig. 2Pathway ontology analysis. Analysis of pathway ontology was realized with PANTHER14.1 Released 2019-03-12 (Protein ANalysis THrough Evolutionary Relationships, <http://pantherdb.org>) \[[@CR19]\]. PANTHER Pathways references are given as well as the percent of gene hits against total genes

In conclusion, we confirmed and identified new protein partners of FAM13A. The future study of these interactions may help to not only understand the overlapping role of FAM13A in chronic lung diseases but their etiology as well.

Limitations {#Sec8}
===========

The limitation of the study is the use of a Human Lung Cancer cDNA library as a prey. Indeed, the proteins identified to interact with FAM13A may be specific of the cancer origins of the cells and my different in a non-pathological context. Also, additional methods will be necessary to confirm these interactions.
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**Additional file 1.** Two-hybrid sequence data.
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